title: Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
abstract: There remains uncertainty over optimal antithrombotic management strategy for patients with atrial fibrillation (AF) presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Clinicians need to balance the risk of stroke and thromboembolism against the risk of recurrent cardiac ischaemia and/or stent thrombosis and the risk of bleeding. The full consensus document comprehensively reviews the published evidence and presents a consensus statement on a 'best practice' antithrombotic therapy guideline for the management of antithrombotic therapy in such AF patients. This executive summary highlights the main recommendations from the consensus document.
authors.affiliation: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK. g.y.h.lip@bham.ac.uk
authors.forename: Gregory Y H
authors.initials: GY
authors.lastname: Lip
authors.forename: Kurt
authors.initials: K
authors.lastname: Huber
authors.forename: Felicita
authors.initials: F
authors.lastname: Andreotti
authors.forename: Harald
authors.initials: H
authors.lastname: Arnesen
authors.forename: Juhani K
authors.initials: JK
authors.lastname: Airaksinen
authors.forename: Thomas
authors.initials: T
authors.lastname: Cuisset
authors.forename: Paulus
authors.initials: P
authors.lastname: Kirchhof
authors.forename: Francisco
authors.initials: F
authors.lastname: Marín
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D005060:Europe; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D012307:Risk Factors; D015607:Stents; D020521:Stroke / Q000517:prevention & control; D013923:Thromboembolism / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents